Therefore, especially in the case of patients with MRD+FLT3+ AML, it may be of use to continue maintenance treatment past the 2-year mark, as FLT3 inhibitors can act on residual leukemic cells to produce IL-15 and maintain GVL response [88,94,95]. Here, FLT3 is linked to acute myeloid leukemia.